Compile Data Set for Download or QSAR
Report error Found 428 Enz. Inhib. hit(s) with all data for entry = 819
TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292767(US10106501, Example DP-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292768(US10106501, Example DP-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292769(US10106501, Example DP-3)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292770(US10106501, Example DU)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292771(US10106501, Example DU1-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292772(US10106501, Example DU1-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292773(US10106501, Example DV)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292774(US10106501, Example DW)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292759(US10106501, Example D-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292761((2,4-dichloro-3-((3,7-dimethyl-5-(trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292762(US10106501, Example DH1-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292763(US10106501, Example DH1-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292764(US10106501, Example DJ1-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292765(US10106501, Example DJ1-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292766(US10106501, Example DJ1-3)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292783(US10106501, Example EE)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292784(US10106501, Example EF)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292785(US10106501, Example EG)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292786(US10106501, Example EG-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292787(US10106501, Example EG-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292788(US10106501, Example EH)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292790(US10106501, Example EI)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292775(US10106501, Example DX)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292776(US10106501, Example DY)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292777(US10106501, Example DZ)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292779(US10106501, Example EA)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292780(US10106501, Example EB)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292781(US10106501, Example EC)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292782(US10106501, Example ED)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292800(US10106501, Example EJ-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292801(US10106501, Example EK)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292802(US10106501, Example EL)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292803(US10106501, Example EL-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292804(US10106501, Example EM)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292805(US10106501, Example EO | US10106501, Example EN)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292805(US10106501, Example EO | US10106501, Example EN)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292807(US10106501, Example EP)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292791(US10106501, Example EI-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292792(US10106501, Example EI-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292793(US10106501, Example EI-3)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292794(US10106501, Example EI-4)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292795(US10106501, Example EI-6 | US10106501, Example EI-...)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292795(US10106501, Example EI-6 | US10106501, Example EI-...)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292798(US10106501, Example EI-7)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292799(US10106501, Example EJ-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292816(US10106501, Example EY)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292817(US10106501, Example EZ)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292818(US10106501, Example F)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292819(US10106501, Example F1-1)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

TargetNuclear receptor ROR-gamma(Human)
Abbvie

US Patent
LigandPNGBDBM292820(US10106501, Example F1-2)
Affinity DataIC50: 100nMAssay Description:The primary screen was performed by transient transactivation assays. These cell-based assays were carried out using Cos-7 cells transfected with a c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
US Patent

Displayed 1 to 50 (of 428 total ) | Next | Last >>
Jump to: